Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
As emerging in the recent literature, CD1a has been regarded as a molecule whose expression may reflect tumour evolution. The aim of the present work was to investigate the expression of CD1a in a series of Barrett's metaplasia (BM), gastric type (GTBM), with and without follow-up, in order to analyse whether its expression may help to diagnose this disease and to address the outcome. Indeed, GTBM may be confused sometimes with islets of ectopic gastric mucosa and its evolution towards dysplasia (Dy) or carcinoma (Ca) could not be foreseen. We showed a significant higher expression of CD1a in GTBM than in both Dy and Ca; nevertheless, the number of positive GTBM was significantly lower in the group of cases that at follow-up underwent Dy or Ca. Our data address that CD1a may be a novel biomarker for BM and that its expression may help to predict the prognosis of this pathology. CD1a is a surface glycoprotein of 43 -49 kDa that has been shown to be expressed by dendritic cells (DCs), cortical thymocytes and Langerhans cells of the skin (Dezutter-Dambuyant et al, 1990;Krenacs et al, 1993;Gregory et al, 2000). Moreover, the research of CD1a is commonly used to differentiate various cutaneous T-cell lymphomas from B-cell lymphomasand pseudolymphomas (Arai et al, 1999;Schmuth et al, 2001).The antitumoral role of CD1a was recently proposed (Coventry and Morton, 2003a;Coventry and Heinzel, 2004;La Rocca et al, 2004). We also recently described that CD1a could be expressed in metaplastic epithelium of Barrett's oesophagus, both gastric and intestinal types, while normal gastric and colonic mucosa were negative to this marker (Cappello et al, 2003). In particular, we postulated that this marker may be useful in diagnosing Barrett's metaplasia (BM) and we hypothesised that its expression could predict a favourable outcome of this disease (Cappello, 2004).Indeed, BM may evolve towards dysplasia (Dy) or carcinoma (Ca) (Cameron and Carpenter, 1997; Malhi-Chowla et al, 2000;Moreto, 2003). Nevertheless, to date, we do not have any marker that could help to predict BM evolution.The aim of the present work was to detect CD1a expression in a large series of BM, Dy and Ca at the time of diagnosis and at follow-up. We would verify the diagnostic role of CD1a for BM and confirm our hypothesis concerning its prognostic role. MATERIALS AND METHODS Sample collectionWe selected retrospectively from our files, 222 cases as follows: 166 specimens were BM of gastric type (GTBM) that underwent follow up; moreover, we selected 37 specimens of Dy and 19 of Ca that did not undergo follow-up. Finally, as control group, we selected 10 specimens from normal gastric mucosa. Sample collection was performed according to ethical standards. In addition, we collected, from the 166 cases of GTBM, the specimens that underwent follow-up, commonly between 12 and 36 months from first diagnosis; in 134 cases, the diagnosis of BM was confirmed (FU-GTBM), while in 23 cases, GTBM evolved towards dysplasia (FU-Dy) and in nine cases towards carcinoma (FU-Ca). Imm...
As emerging in the recent literature, CD1a has been regarded as a molecule whose expression may reflect tumour evolution. The aim of the present work was to investigate the expression of CD1a in a series of Barrett's metaplasia (BM), gastric type (GTBM), with and without follow-up, in order to analyse whether its expression may help to diagnose this disease and to address the outcome. Indeed, GTBM may be confused sometimes with islets of ectopic gastric mucosa and its evolution towards dysplasia (Dy) or carcinoma (Ca) could not be foreseen. We showed a significant higher expression of CD1a in GTBM than in both Dy and Ca; nevertheless, the number of positive GTBM was significantly lower in the group of cases that at follow-up underwent Dy or Ca. Our data address that CD1a may be a novel biomarker for BM and that its expression may help to predict the prognosis of this pathology. CD1a is a surface glycoprotein of 43 -49 kDa that has been shown to be expressed by dendritic cells (DCs), cortical thymocytes and Langerhans cells of the skin (Dezutter-Dambuyant et al, 1990;Krenacs et al, 1993;Gregory et al, 2000). Moreover, the research of CD1a is commonly used to differentiate various cutaneous T-cell lymphomas from B-cell lymphomasand pseudolymphomas (Arai et al, 1999;Schmuth et al, 2001).The antitumoral role of CD1a was recently proposed (Coventry and Morton, 2003a;Coventry and Heinzel, 2004;La Rocca et al, 2004). We also recently described that CD1a could be expressed in metaplastic epithelium of Barrett's oesophagus, both gastric and intestinal types, while normal gastric and colonic mucosa were negative to this marker (Cappello et al, 2003). In particular, we postulated that this marker may be useful in diagnosing Barrett's metaplasia (BM) and we hypothesised that its expression could predict a favourable outcome of this disease (Cappello, 2004).Indeed, BM may evolve towards dysplasia (Dy) or carcinoma (Ca) (Cameron and Carpenter, 1997; Malhi-Chowla et al, 2000;Moreto, 2003). Nevertheless, to date, we do not have any marker that could help to predict BM evolution.The aim of the present work was to detect CD1a expression in a large series of BM, Dy and Ca at the time of diagnosis and at follow-up. We would verify the diagnostic role of CD1a for BM and confirm our hypothesis concerning its prognostic role. MATERIALS AND METHODS Sample collectionWe selected retrospectively from our files, 222 cases as follows: 166 specimens were BM of gastric type (GTBM) that underwent follow up; moreover, we selected 37 specimens of Dy and 19 of Ca that did not undergo follow-up. Finally, as control group, we selected 10 specimens from normal gastric mucosa. Sample collection was performed according to ethical standards. In addition, we collected, from the 166 cases of GTBM, the specimens that underwent follow-up, commonly between 12 and 36 months from first diagnosis; in 134 cases, the diagnosis of BM was confirmed (FU-GTBM), while in 23 cases, GTBM evolved towards dysplasia (FU-Dy) and in nine cases towards carcinoma (FU-Ca). Imm...
BACKGROUND:In contrast to other primary thyroid neoplasms and benign thyroid tissue, it has been demonstrated histologically that dendritic cells (DCs) are associated with papillary thyroid carcinoma (PTC). However, the presence and potential diagnostic value of DCs in thyroid fine-needle aspirations (FNAs) have not been previously described. METHODS: The authors quantitatively assessed for the presence of DCs that were positive for cluster of differentiation 1a (CD1a) (a 43-49 kD protein expressed on DCs and cortical thymocytes) in cytologic samples of histologically confirmed PTC (n ¼ 31) and in a control group of benign thyroid nodules (BTNs) (n ¼ 29) using immunocytochemical staining with antibodies against CD1a.A subset of the corresponding PTCs (n ¼ 11) and BTNs (n ¼ 10) from surgical resection specimens also were assessed immunohistochemically for both CD1a and Langerin (a type II transmembrane cell surface receptor produced by Langerhans cells).RESULTS: CD1a-positive DCs were identified in 97% PTCs (n ¼ 30 of 31 PTCs) in thyroid FNA specimens. DCs were largely present in 2 distinct patterns: either as isolated DCs in the background (n ¼ 29 of 31) and/or associated with tumor cells (n ¼ 30 of 31). Tumor-associated DCs (mean AE standard deviation: 6.44 AE 6.13 DCs per tumor cluster) exhibited multiple dendritic cytoplasmic processes extending over and between malignant cells within groups. The 3 PTC cases with the least DCs corresponded to the follicular variant at excision. In contrast, only 31% of BTNs (n ¼ 9 of 29 BTNs; P ¼ .0048) contained CD1a-positive DCs. When DCs were present in BTN, they were isolated primarily in the background (27%; n ¼ 8 of 29), although 17% of BTNs (n ¼ 5 of 29) contained rare DCs among thyrocytes, revealing both patterns in 4 cases. Both thyrocyte-associated DCs and background DCs were more numerous in PTC FNAs than in BTN FNAs, but only the thyrocyte-associated group of DCs was statistically significant (P < .0001 and P ¼ .1173, respectively). Similar findings were reported in histologic samples in which all PTCs examined (n ¼ 11 of 11) contained both CD1a-positive and Langerin-positive DCs; only 20% of BTNs (n ¼ 2 of 10) contained rare DCs. CONCLUSIONS: CD1a-positive DCs were present in FNA specimens of PTC, typically in close association with tumor cells, whereas they were rare in BTNs. The increased presence of CD1a-positive DCs in PTC may be a useful diagnostic adjuvant. Cancer (Cancer Cytopathol) 2013;121:206-13.
CD1a expression is considered one of the major characteristics qualifying in vitro human dendritic cells (DCs) during their generation process. Here, we report that CD1A transcription is regulated by a mechanism involving the long and short isoforms of CD99. Using a lentiviral construct encoding for a CD99 short hairpin RNA, we were able to inhibit CD99 expression in human primary DCs. In such cells, CD1a membrane expression increased and CD1A transcripts were much higher in abundance compared to cells expressing CD99 long form (CD99LF). We also show that CD1A transcription is accompanied by a switch in expression from CD99LF to expression at comparable levels of both CD99 isoforms during immature DCs generation in vitro. We demonstrate that CD99LF maintains a lower level of CD1A transcription by up-regulating the phosphorylated form of the ATF-2 transcription factor and that CD99 short form (SF) is required to counteract this regulatory mechanism. Elucidation of the molecular mechanisms related to CD99 alternative splicing will be very helpful to better understand the transcriptional regulatory mechanism of CD1a molecules during DCs differentiation and its involvement in the immune response.Keywords: alternative splicing-ATF2-CREB1 r CD99 r Dendritic cells r Nonclassical MHC Additional supporting information may be found in the online version of this article at the publisher's web-site IntroductionPresentation of foreign antigens in the form of proteins or lipids solicits specialized molecular complexes carried by dendritic cells (DCs). The molecules of the classical and nonclassical major Correspondence: Dr. Ghislaine Bernard e-mail: bernardg@unice.fr histocompatibility complex (MHC) class I present antigens to T cells and these two families of molecules have very similar structures [1][2][3].Among the nonclassical MHC molecules is the CD1 family of molecules that assures the presentation of lipid and glycolipid † Deceased C 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu Eur. J. Immunol. 2016. 46: 1460-1471 Immunomodulation 1461 antigens [4,5]. This family consists of five genes, including CD1A, B, C, D and E. The first four give rise to cell surface proteins CD1a, CD1b, CD1c, CD1d that are able to present the antigens, while the gene CD1E codes for the cytoplasmic protein CD1e [6][7][8]. CD1a is expressed on the membranes of thymocytes, dermal DCs and Langerhans cells, and allows distinction between subpopulations of DCs. No such equivalent has been reported in mice [8].CD1a is expressed during generation of DCs derived from monocytes when cultured in the presence of GMCSF and IL4 in vitro [9]. Two subpopulations of immature DCs (iDCs), i.e. CD1a high and CD1a low DCs, are produced in these conditions [10,11]. In addition to their phenotypic differences, these cells show functional differences, in particular in terms of secretion of cytokines. In contrast to CD1a high DCs, CD1a low DCs produce low amounts of IL12 but produce high amounts of IL10. This profile of cytokines impacts on the f...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.